cyclophosphamide

Type: Keyphrase
Name: cyclophosphamide
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Anthracyclines and Taxanes in Breast Cancer Treatment

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71–85.Mauri ... [Published General Medicine eJournal - 9 hours ago]
First reported 17 hours ago - Updated 17 hours ago - 1 reports

High Response Rate and Good Safety Profile for Carfilzomib Plus Cyclophosphamide and Dexamethasone

By Charlotte BathJuly 25, 2014, Volume 5, Issue 12A multicenter, open-label phase II trial found that the selective proteasome inhibitor carfilzomib (Kyprolis), in combination with cyclophosphamide and dexamethasone produced high complete response rates ... [Published The ASCO Post - 17 hours ago]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Anti-Tumor Drugs Market: Industry Size and Analysis 2019

Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be subcategorized as benign and malignant. Benign is not destructive however, possess a ... [Published MyNewsDesk - Jul 22 2014]
Entities: Tumor, Market, Cancer
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

EU project The Body-on-a-Chip

InSphero has co-authored research published in the journal Nature Communications that demonstrates the feasibility of creating multi-tissue networks of spheroids in a hanging drop format, interconnected by microfluidic channels. The publication is the ... [Published Select Science - Jul 21 2014]
First reported Jul 20 2014 - Updated Jul 20 2014 - 1 reports

Rebound post-natallizumab: it is not as bad as it seems

Rebound post-natalizumab: is it such a problem? #MSBlog #MSResearch "The study below reports MS rebound post-natalizumab. They make a general statement that 'no treatment is unable to abolish disease activity reactivation after natalizumab discontinuation' ... [Published Multiple Sclerosis Research - Jul 20 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 2 reports

Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide

(GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of ... [Published Virtual Strategy Magazine - Jul 17 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Cardiotoxicity following cyclophosphamide therapy: a case report

IntroductionCardiac toxicity is one of the life-threatening complications of cancer therapy. Systemic anticancer treatments may exert their own toxic effects or can aggravate adverse effects of other drugs.We report a case of cyclophosphamide-induced ... [Published 7thSpace - Jul 14 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 2 reports

A vaccine may cause pancreatic cancer to respond to immunotherapy

(Medical Xpress)—Pancreatic ductal adenocarcinomas (PDAC) do not typically respond to immunotherapy, which limits treatment options for this cancer. By priming with a therapeutic vaccine and a low-dose chemotherapy combination prior to surgery, researchers ... [Published Medical Xpress - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Largest Study of Consolidation Therapy for Ewing's Sarcoma

As consolidation therapy for Ewing's sarcoma, there is little difference in the cure rate between cyclophosphamide and ifosfamide, new research shows.The largest randomized controlled trial to date, known as Euro-EWING99-R1, looked at these therapies ... [Published Diabetes Care - Jul 09 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Cyclophosphamide Effective Substitute for Ifosfamide in Ewing Sarcoma

Clinicians may be able to safely substitute cyclophosphamide for ifosfamide in the consolidation treatment of standard-risk Ewing sarcoma, according to the results of the Euro-EWING99-R1 trial published in the Journal of Clinical Oncology .“These results ... [Published Cancernetwork.com - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial [Pediatric Oncology]

AbstractPurpose Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial askedwhether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, d ... [Published Journal of Clinical Oncology - Jul 01 2014]
First reported Jun 27 2014 - Updated Jun 28 2014 - 2 reports

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency (EMA) to expand the label for VELCADE ® (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin ... [Published News-Medical.Net - Jun 28 2014]

Quotes

According to the news editors, the research concluded: "Results may be affected by selection biases where less aggressive regimens are offered to frailer patients."
"Additional examples of conditions that may be treated using the disclosed compounds and compositions include solid tumors, such as sarcomas and carcinomas, including, but not limited to fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, cyclophosphamide-resistant sarcomas, and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms tumor, cervical cancer, testicular tumor, bladder carcinoma, and CNS tumors (such as a glioma, astrocytoma, medulloblastoma, craniopharyogioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma and retinoblastoma)."

More Content

All (153) | News (139) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Anthracyclines and Taxanes in Breast Cancer Tre... [Published General Medicine eJournal - 9 hours ago]
High Response Rate and Good Safety Profile for ... [Published The ASCO Post - 17 hours ago]
Belinostat for Relapsed/Refractory Peripheral T... [Published The ASCO Post - 21 hours ago]
Findings on Breast Cancer Discussed by Investig... [Published 4 Traders - Jul 24 2014]
ZIOPHARM Oncology : Patent Application Titled "... [Published 4 Traders - Jul 24 2014]
FDA Approves Belinostat for Relapsed or Refract... [Published The ASCO Post - Jul 23 2014]
Johnson & Johnson Reports 2014 Second-Quarter R... [Published HispanicBusiness.com - Jul 23 2014]
Scleroderma Diagnostics And Therapeutics Market... [Published MyNewsDesk - Jul 23 2014]
Non-Hodgkins Lymphoma Therapeutics Market - Glo... [Published MyNewsDesk - Jul 22 2014]
Anti-Tumor Drugs Market: Industry Size and Anal... [Published MyNewsDesk - Jul 22 2014]
Rituximab for the treatment of relapses in ANCA... [Published Arthritis & Rheumatism - Jul 21 2014]
EU project The Body-on-a-Chip [Published Select Science - Jul 21 2014]
Rebound post-natallizumab: it is not as bad as ... [Published Multiple Sclerosis Research - Jul 20 2014]
System 'prints' precise drug dosages tailored f... [Published Purdue University - Jul 18 2014]
Hematological Malignancy Takeaways from ASCO 2014 [Published Oncology Times - Jul 18 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
BrainStorm's Clinical Trial is Fast-Tracked to ... [Published BioMedReports - Jul 18 2014]
Baxter International (BAX) CEO Discusses Q2 201... [Published Seeking Alpha - Jul 17 2014]
UPDATE 2-Gambro acquisition boosts Baxter's sales [Published CNBC - Jul 17 2014]
Nuvilex and Austrianova Announce Results of Cli... [Published GlobeNewswire: Acquisitions News - Jul 17 2014]
Nuvilex and Austrianova Announce Results of Cli... [Published Virtual Strategy Magazine - Jul 17 2014]
Nuvilex and Austrianova Announce Results of Cli... [Published Crawford Financial Planning - Jul 17 2014]
CLL: RESONATE Ibrutinib Study Called Practice C... [Published Oncology Times - Jul 17 2014]
Rheumatoid Arthritis and Lung Disease: A Practi... [Published General Medicine eJournal - Jul 17 2014]
Combination treatment with oncolytic Vaccinia v... [Published 7thSpace - Jul 17 2014]
Study Results from Department of Laboratory Med... [Published 4 Traders - Jul 16 2014]
Carfilzomib combination highly effective in old... [Published Orthopedics Today - Jul 16 2014]
AGO Recommendations for the Diagnosis and Treat... [Published Sexual Development - Jul 16 2014]
The spare tyre syndrome [Published Men's Health India - Jul 15 2014]
Comparison of molecular and immunocytochemical ... [Published 7thSpace - Jul 15 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Rebound post-natallizumab: it is not as bad as ... [Published Multiple Sclerosis Research - Jul 20 2014]
Rebound post-natalizumab: is it such a problem? #MSBlog #MSResearch "The study below reports MS rebound post-natalizumab. They make a general statement that 'no treatment is unable to abolish disease activity reactivation after natalizumab discontinuation' ...
Fatherhood and MS medications [Published MSology - Jul 10 2014]
A great deal has been written about MS and pregnancy. The general rule of thumb is that women who plan to become pregnant should interrupt their MS medication, then resume treatment once the baby is born. (For more on this topic, see Is it Safe to ...
Janssen files EU marketing application for VELC... [Published PBR - News - Jun 30 2014]
Janssen-Cilag International has announced its submission of a type II variation to the European Medicines Agency (EMA) to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, ...
Australian Woman Poisons Daughter to Get Facebo... [Published TIME.com - Jun 11 2014]
An Australian mother has been jailed for deliberately poisoning her otherwise healthy 4-year-old daughter with chemotherapy drugs. Over a nine-month period, the 23-year-old woman used the Internet to procure the cancer treatment drug cyclophosphamide ...
Some Chemotherapy Is More Toxic Than Others [Published TIME.com - May 28 2014]
Researchers at the University of Texas MD Anderson Cancer Center compared six breast cancer chemotherapy regimens to determine which caused more toxic side effects by requiring the patients to be hospitalized for infections, fever, dehydration or low ...
1 2 3

Press Releases

sort by: Date | Relevance
Nuvilex and Austrianova Announce Results of Cli... [Published GlobeNewswire: Acquisitions News - Jul 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.